macroliden

Macrolides are a class of broad-spectrum antibiotics derived from the fermentation of certain bacteria, primarily Streptomyces species. They are characterized by a large macrocyclic lactone ring, typically containing 12 to 16 atoms, which distinguishes them from other antibiotic classes. Macrolides are primarily used to treat bacterial infections caused by gram-positive cocci, gram-negative bacilli, and atypical pathogens such as Chlamydia, Mycoplasma, and Legionella species.

The first macrolide antibiotic, erythromycin, was discovered in 1952 and remains one of the most widely used members of the class. Other notable macrolides include clarithromycin, azithromycin, and telithromycin, each with variations in spectrum, potency, and pharmacokinetic properties. Macrolides exert their antibacterial effects by inhibiting bacterial protein synthesis. They bind to the 50S subunit of the bacterial ribosome, preventing the translocation step of translation, which halts protein production essential for bacterial survival.

Macrolides are generally well-tolerated, though side effects such as gastrointestinal disturbances (e.g., nausea, diarrhea) and rare but serious reactions like hepatotoxicity or QT interval prolongation (particularly with telithromycin) may occur. They are often prescribed for respiratory tract infections, skin and soft tissue infections, and sexually transmitted diseases. Resistance to macrolides has emerged due to methylation of the ribosomal target site or efflux pump mechanisms, limiting their efficacy in some cases.

Macrolides are available in oral, intravenous, and topical formulations, with azithromycin and clarithromycin being commonly used for outpatient treatment. They are also utilized in combination therapies for conditions such as Helicobacter pylori infection and certain parasitic diseases. Due to their relatively low toxicity compared to other antibiotics, macrolides remain a valuable option in clinical practice.